Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency
Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis....
Gespeichert in:
Veröffentlicht in: | Baillière's best practice & research. Clinical gastroenterology 2001-06, Vol.15 (3), p.477-486 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 486 |
---|---|
container_issue | 3 |
container_start_page | 477 |
container_title | Baillière's best practice & research. Clinical gastroenterology |
container_volume | 15 |
creator | DiMagno, Eugene P. |
description | Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea. |
doi_str_mv | 10.1053/bega.2001.0195 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70926534</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521691801901957</els_id><sourcerecordid>70926534</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</originalsourceid><addsrcrecordid>eNp1kMFLwzAUh4Mobk6vHqUnb615SZM1Rxk6hYEgeg5Z8iKRra1JO9x_b-sGnjy9B-_7_eB9hFwDLYAKfrfGD1MwSqGgoMQJmYLgLAcF8nTcGeRSQTUhFyl90gGTSp2TCUBJuSjplLwuTepisJmxwWWpb9uIKYWmzkztsi6i6bZYd1njs4Q7jJjhd2NjqDFrTW3H-xAOdeq9DzZgbfeX5MybTcKr45yR98eHt8VTvnpZPi_uV7ktuejyUiFw4Z1kTqIthfLMVY56CTivOJtThZKBpVIxzszaC68clMC4ZKicr_iM3B5629h89Zg6vQ3J4mZjamz6pIcGJgUvB7A4gDY2KUX0uo1ha-JeA9WjRT1a1KNFPVocAjfH5n69RfeHH7UNQHUAcPhvFzDq9Ps7uhDRdto14b_uH0higUc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70926534</pqid></control><display><type>article</type><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>DiMagno, Eugene P.</creator><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><description>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</description><identifier>ISSN: 1521-6918</identifier><identifier>EISSN: 1532-1916</identifier><identifier>DOI: 10.1053/bega.2001.0195</identifier><identifier>PMID: 11403540</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anti-Ulcer Agents - therapeutic use ; chronic pancreatitis ; cystic fibrosis ; exocrine pancreatic insufficiency ; Exocrine Pancreatic Insufficiency - drug therapy ; Gastric Acid - physiology ; H2-receptor inhibitors ; Humans ; lipase ; lipolytic activity ; malabsorption ; Pancreas - drug effects ; Pancreas - pathology ; pancreatic enzymes ; proton pump inhibitors ; steatorrhoea</subject><ispartof>Baillière's best practice & research. Clinical gastroenterology, 2001-06, Vol.15 (3), p.477-486</ispartof><rights>2001 Harcourt Publishers Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</citedby><cites>FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/bega.2001.0195$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11403540$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><title>Baillière's best practice & research. Clinical gastroenterology</title><addtitle>Best Pract Res Clin Gastroenterol</addtitle><description>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</description><subject>Anti-Ulcer Agents - therapeutic use</subject><subject>chronic pancreatitis</subject><subject>cystic fibrosis</subject><subject>exocrine pancreatic insufficiency</subject><subject>Exocrine Pancreatic Insufficiency - drug therapy</subject><subject>Gastric Acid - physiology</subject><subject>H2-receptor inhibitors</subject><subject>Humans</subject><subject>lipase</subject><subject>lipolytic activity</subject><subject>malabsorption</subject><subject>Pancreas - drug effects</subject><subject>Pancreas - pathology</subject><subject>pancreatic enzymes</subject><subject>proton pump inhibitors</subject><subject>steatorrhoea</subject><issn>1521-6918</issn><issn>1532-1916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFLwzAUh4Mobk6vHqUnb615SZM1Rxk6hYEgeg5Z8iKRra1JO9x_b-sGnjy9B-_7_eB9hFwDLYAKfrfGD1MwSqGgoMQJmYLgLAcF8nTcGeRSQTUhFyl90gGTSp2TCUBJuSjplLwuTepisJmxwWWpb9uIKYWmzkztsi6i6bZYd1njs4Q7jJjhd2NjqDFrTW3H-xAOdeq9DzZgbfeX5MybTcKr45yR98eHt8VTvnpZPi_uV7ktuejyUiFw4Z1kTqIthfLMVY56CTivOJtThZKBpVIxzszaC68clMC4ZKicr_iM3B5629h89Zg6vQ3J4mZjamz6pIcGJgUvB7A4gDY2KUX0uo1ha-JeA9WjRT1a1KNFPVocAjfH5n69RfeHH7UNQHUAcPhvFzDq9Ps7uhDRdto14b_uH0higUc</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>DiMagno, Eugene P.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</title><author>DiMagno, Eugene P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-49e135fd62d6ec459f2d8d0f61e7832709e621c069232abf5f9d1412362e9df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Anti-Ulcer Agents - therapeutic use</topic><topic>chronic pancreatitis</topic><topic>cystic fibrosis</topic><topic>exocrine pancreatic insufficiency</topic><topic>Exocrine Pancreatic Insufficiency - drug therapy</topic><topic>Gastric Acid - physiology</topic><topic>H2-receptor inhibitors</topic><topic>Humans</topic><topic>lipase</topic><topic>lipolytic activity</topic><topic>malabsorption</topic><topic>Pancreas - drug effects</topic><topic>Pancreas - pathology</topic><topic>pancreatic enzymes</topic><topic>proton pump inhibitors</topic><topic>steatorrhoea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DiMagno, Eugene P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DiMagno, Eugene P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency</atitle><jtitle>Baillière's best practice & research. Clinical gastroenterology</jtitle><addtitle>Best Pract Res Clin Gastroenterol</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>15</volume><issue>3</issue><spage>477</spage><epage>486</epage><pages>477-486</pages><issn>1521-6918</issn><eissn>1532-1916</eissn><abstract>Adding either H2-receptor antagonists (cimetidine or ranitidine) or proton pump inhibitors to an adequate amount of lipolytic activity improves fat malabsorption in most cases and abolishes steatorrhoea in up to 40% of children and adults with cystic fibrosis and in adults with chronic pancreatitis. Acid suppression improves fat absorption because the resultant increase in pH within the upper gastrointestinal tract improves the survival of lipolytic activity, reduces duodenal volume flow and prevents the precipitation of bile acids. These effects increase the concentration of intraduodenal lipolytic activity and promote the aggregation of bile acids and the micellar solubilization of lipid. The amount of lipase that should be recommended is controversial, but we interpret our studies as indicating that at least 90000 United States Pharmacopeia (USP) units should be ingested with meals. This amount of lipolytic activity taken with an agent that suppresses gastric acid secretion improves fat absorption in most patients and may even abolish steatorrhoea.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>11403540</pmid><doi>10.1053/bega.2001.0195</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1521-6918 |
ispartof | Baillière's best practice & research. Clinical gastroenterology, 2001-06, Vol.15 (3), p.477-486 |
issn | 1521-6918 1532-1916 |
language | eng |
recordid | cdi_proquest_miscellaneous_70926534 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Anti-Ulcer Agents - therapeutic use chronic pancreatitis cystic fibrosis exocrine pancreatic insufficiency Exocrine Pancreatic Insufficiency - drug therapy Gastric Acid - physiology H2-receptor inhibitors Humans lipase lipolytic activity malabsorption Pancreas - drug effects Pancreas - pathology pancreatic enzymes proton pump inhibitors steatorrhoea |
title | Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A40%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastric%20acid%20suppression%20and%20treatment%20of%20severe%20exocrine%20pancreatic%20insufficiency&rft.jtitle=Bailli%C3%A8re's%20best%20practice%20&%20research.%20Clinical%20gastroenterology&rft.au=DiMagno,%20Eugene%20P.&rft.date=2001-06-01&rft.volume=15&rft.issue=3&rft.spage=477&rft.epage=486&rft.pages=477-486&rft.issn=1521-6918&rft.eissn=1532-1916&rft_id=info:doi/10.1053/bega.2001.0195&rft_dat=%3Cproquest_cross%3E70926534%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70926534&rft_id=info:pmid/11403540&rft_els_id=S1521691801901957&rfr_iscdi=true |